Laserfiche Joins the Boomi Technology Partner Program, Supporting the Automated, Connected Enterprise
22.2.2023 17:00:00 EET | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced a partnership with Boomi, a leading provider of integration platform as a service known for its speed, ease-of-use, and low total cost of ownership. Through this partnership, organizations can simplify integrations between Laserfiche's robust content services platform and on-premises and cloud applications such as Salesforce, Workday, and Smartsheet using Boomi’s connectors to over 1,500 applications.
“Today’s connected enterprise is built on a robust technology infrastructure, which requires a centralized system to collect and monitor process data, paired with a simplified integration strategy,” said David Everson, Laserfiche’s senior director of strategic solutions. “Laserfiche is excited to bring a proven system for data centralization and process automation to the Boomi ecosystem, enabling more speed, greater agility and stronger security in our customers’ integrations.”
Laserfiche supports organizations in building end-to-end automated solutions that boost productivity, scale with growth and deliver digital-first customer experiences. Laserfiche customers can now take advantage of the enterprise content management (ECM) platform’s Boomi-powered connectors to mission-critical line-of-business applications accelerate integration deployment, more easily manage integration lifecycles and access organization-wide data analytics. The Laserfiche and Boomi partnership is enabling customers to configure and expedite solutions such as:
- Streamlined recruiting and new employee onboarding to move candidates through the hiring process quickly
- Sending/retrieving data to/from popular storage and databases for more flexible data queries and reporting
- Streamlined invoice processing to gain real-time visibility into accounts payable
- Syncing client updates to provide the business with a more holistic view of the client
- Simplified authentication for secure connections to applications
According to The Forrester Wave™: Enterprise iPaaS, Q4 2021, “As more organizations embrace cloud-native, applications and data are more distributed than ever before. Delivering those user experiences and digital business capabilities requires an integration platform that stitches together the ever-growing number of distributed apps and data. Furthermore, the pandemic and quarantines accelerated the need for business process automation and has squeezed IT beyond what it can deliver. In response, organizations are embracing citizen iPaaS as a tool in their business process automation strategy.”
The Boomi Technology Partner Program includes enterprise software companies across applications such as CRM, ERP, HRIS and business intelligence, as well as across industries including government, education, financial services, healthcare and manufacturing. Boomi provides organizations with greater scalability and greater control over data orchestration between application transactions, allowing connectivity to scale as organizations adopt a wider range of solutions.
“We are excited to have Laserfiche as part of our Technology Partnership Program,” said Reggie Penn, global head of technology alliances at Boomi. “A leader in the enterprise content management space, Laserfiche is a solid addition to our profile of partners that offer real solutions that help organizations solve their biggest challenges. The collaboration between Laserfiche and Boomi positions our mutual customers to meet the growing demand for integrations and keep up with the rapid pace of innovation.”
Learn more about the Laserfiche and Boomi partnership by visiting the Laserfiche website.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter | LinkedIn | Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005010/en/
Contact information
Linda Domingo
Director, Public Relations, Laserfiche
Linda.domingo@laserfiche.com
562-988-1688 ext. 234
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
